patient_id stringlengths 20 22 | cancer_type stringclasses 1 value | histology stringclasses 2 values | stage_at_diagnosis stringclasses 2 values | molecular_profile dict | baseline_clinical dict | disease_burden_at_dx dict | treatment_course dict | survival_outcomes dict | longitudinal_labs listlengths 3 3 |
|---|---|---|---|---|---|---|---|---|---|
ANODE_SYNTH_2025_001 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 48,
"sex": "female",
"bmi": 32.6,
"smoking_pack_years": 55,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"pleura",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-02-11T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -46
},
"pfs_months": 10.64
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-01-20T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 19.2,
"censored": false
} | [
{
"date": "2023-01-16T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 9.3,
"platelets_k_uL": 187,
"creatinine_mg_dL": 1.16,
"alt_U_L": 17
},
{
"date": "2023-08-10T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 7,
"platelets_k_uL": 178,
"creatinine_mg_dL": 1.04,
"... |
ANODE_SYNTH_2025_002 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 72,
"sex": "female",
"bmi": 21.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7.3,
"metastatic_sites": [
"contralateral lung",
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-07-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -51,
"peak_response_20wk_change_percent": -76
},
"pfs_months": 18.33
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-02-23T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 29.3,
"censored": true
} | [
{
"date": "2025-06-09T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 7.6,
"platelets_k_uL": 310,
"creatinine_mg_dL": 0.89,
"alt_U_L": 72
},
{
"date": "2026-01-18T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 7.4,
"platelets_k_uL": 233,
"creatinine_mg_dL": 1.1,
... |
ANODE_SYNTH_2025_003 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 11
} | {
"age": 57,
"sex": "male",
"bmi": 19.3,
"smoking_pack_years": 53,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.5,
"metastatic_sites": [
"bone",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-11-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -45
},
"pfs_months": 3.81
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-04-25T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 7.8,
"censored": false
} | [
{
"date": "2021-10-23T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 8.5,
"platelets_k_uL": 259,
"creatinine_mg_dL": 0.89,
"alt_U_L": 68
},
{
"date": "2022-05-21T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 7.7,
"platelets_k_uL": 363,
"creatinine_mg_dL": 1.31,
... |
ANODE_SYNTH_2025_004 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3
} | {
"age": 67,
"sex": "female",
"bmi": 18.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 5.9,
"metastatic_sites": [
"brain",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-07-29T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -81
},
"pfs_months": 22.24
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-07-16T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 35.8,
"censored": true
} | [
{
"date": "2025-06-03T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 4.9,
"platelets_k_uL": 435,
"creatinine_mg_dL": 1.05,
"alt_U_L": 74
},
{
"date": "2026-01-25T00:00:00",
"hemoglobin_g_dL": 10.5,
"wbc_k_uL": 5.4,
"platelets_k_uL": 136,
"creatinine_mg_dL": 1.22,
... |
ANODE_SYNTH_2025_005 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 68,
"sex": "male",
"bmi": 30.8,
"smoking_pack_years": 57,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 4,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-05-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -23,
"peak_response_20wk_change_percent": -49
},
"pfs_months": 41.13
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-12-09T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 55.6,
"censored": false
} | [
{
"date": "2022-04-24T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 10.6,
"platelets_k_uL": 336,
"creatinine_mg_dL": 0.8,
"alt_U_L": 35
},
{
"date": "2022-11-26T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 6.2,
"platelets_k_uL": 207,
"creatinine_mg_dL": 0.84,
... |
ANODE_SYNTH_2025_006 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 49,
"sex": "female",
"bmi": 30.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.9,
"metastatic_sites": [
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-11-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 7.56
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-09-01T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 26,
"censored": true
} | [
{
"date": "2022-09-24T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 9.1,
"platelets_k_uL": 213,
"creatinine_mg_dL": 1.17,
"alt_U_L": 46
},
{
"date": "2023-05-22T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 7.6,
"platelets_k_uL": 167,
"creatinine_mg_dL": 1.04,
... |
ANODE_SYNTH_2025_007 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 52,
"sex": "female",
"bmi": 27,
"smoking_pack_years": 38,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.1,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-12-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -26,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 22.28
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-11-08T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 41.1,
"censored": false
} | [
{
"date": "2020-11-10T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 8.3,
"platelets_k_uL": 373,
"creatinine_mg_dL": 1.17,
"alt_U_L": 27
},
{
"date": "2021-06-12T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 4.1,
"platelets_k_uL": 202,
"creatinine_mg_dL": 0.95,
... |
ANODE_SYNTH_2025_008 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 3.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 85,
"sex": "female",
"bmi": 19.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.1,
"metastatic_sites": [
"brain",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-02-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -58
},
"pfs_months": 22.31
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-12-30T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 41.6,
"censored": true
} | [
{
"date": "2024-12-20T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 8,
"platelets_k_uL": 152,
"creatinine_mg_dL": 0.8,
"alt_U_L": 53
},
{
"date": "2025-08-05T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 9,
"platelets_k_uL": 379,
"creatinine_mg_dL": 1.33,
"alt... |
ANODE_SYNTH_2025_009 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 55,
"sex": "female",
"bmi": 21.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"contralateral lung",
"pleura",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-11-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -55,
"peak_response_20wk_change_percent": -75
},
"pfs_months": 19.58
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-07-15T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 41.5,
"censored": false
} | [
{
"date": "2021-10-06T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 10.7,
"platelets_k_uL": 188,
"creatinine_mg_dL": 0.69,
"alt_U_L": 45
},
{
"date": "2022-05-14T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 4.5,
"platelets_k_uL": 165,
"creatinine_mg_dL": 0.79,
... |
ANODE_SYNTH_2025_010 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 56,
"sex": "female",
"bmi": 33.4,
"smoking_pack_years": 57,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-07-06T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 26.48
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-11-02T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 33.3,
"censored": true
} | [
{
"date": "2023-05-11T00:00:00",
"hemoglobin_g_dL": 15,
"wbc_k_uL": 6.5,
"platelets_k_uL": 229,
"creatinine_mg_dL": 1.19,
"alt_U_L": 50
},
{
"date": "2024-01-02T00:00:00",
"hemoglobin_g_dL": 10.5,
"wbc_k_uL": 7,
"platelets_k_uL": 315,
"creatinine_mg_dL": 1.59,
"al... |
ANODE_SYNTH_2025_011 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 78,
"sex": "female",
"bmi": 18.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-12-26T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -40
},
"pfs_months": 26.32
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-04-02T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 39.2,
"censored": false
} | [
{
"date": "2023-11-22T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 6.2,
"platelets_k_uL": 213,
"creatinine_mg_dL": 1.14,
"alt_U_L": 40
},
{
"date": "2024-06-23T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 7,
"platelets_k_uL": 228,
"creatinine_mg_dL": 1.16,
"... |
ANODE_SYNTH_2025_012 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 56,
"sex": "female",
"bmi": 35.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"contralateral lung",
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-07-12T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -35
},
"pfs_months": 24.41
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-09-15T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 39.6,
"censored": false
} | [
{
"date": "2022-06-09T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 9,
"platelets_k_uL": 212,
"creatinine_mg_dL": 0.72,
"alt_U_L": 40
},
{
"date": "2023-01-08T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 7,
"platelets_k_uL": 136,
"creatinine_mg_dL": 1.17,
"al... |
ANODE_SYNTH_2025_013 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 82,
"sex": "female",
"bmi": 19.8,
"smoking_pack_years": 24,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-05-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -51,
"peak_response_20wk_change_percent": -38
},
"pfs_months": 19.75
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-02-10T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 40.4,
"censored": false
} | [
{
"date": "2025-03-13T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 9.8,
"platelets_k_uL": 350,
"creatinine_mg_dL": 0.87,
"alt_U_L": 76
},
{
"date": "2025-11-02T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 8.1,
"platelets_k_uL": 121,
"creatinine_mg_dL": 1.08,
"... |
ANODE_SYNTH_2025_014 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3
} | {
"age": 76,
"sex": "male",
"bmi": 34.8,
"smoking_pack_years": 65,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"pleura",
"brain",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-07-29T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -38
},
"pfs_months": 17.58
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-02-08T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 31.6,
"censored": false
} | [
{
"date": "2022-05-27T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 5,
"platelets_k_uL": 443,
"creatinine_mg_dL": 1.08,
"alt_U_L": 66
},
{
"date": "2023-01-25T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 6.6,
"platelets_k_uL": 342,
"creatinine_mg_dL": 1.14,
"... |
ANODE_SYNTH_2025_015 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 73,
"sex": "female",
"bmi": 28.5,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-08-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -20,
"peak_response_20wk_change_percent": -31
},
"pfs_months": 20.11
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-06-18T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 35.4,
"censored": false
} | [
{
"date": "2020-07-18T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 6,
"platelets_k_uL": 375,
"creatinine_mg_dL": 0.6,
"alt_U_L": 15
},
{
"date": "2021-02-21T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 5.1,
"platelets_k_uL": 209,
"creatinine_mg_dL": 1.02,
"a... |
ANODE_SYNTH_2025_016 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 49,
"sex": "male",
"bmi": 28.5,
"smoking_pack_years": 52,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-10-02T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -71
},
"pfs_months": 16.16
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-03-08T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 33.3,
"censored": false
} | [
{
"date": "2020-08-20T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 8.9,
"platelets_k_uL": 235,
"creatinine_mg_dL": 1.01,
"alt_U_L": 47
},
{
"date": "2021-03-31T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 8.3,
"platelets_k_uL": 174,
"creatinine_mg_dL": 1.3,
... |
ANODE_SYNTH_2025_017 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19
} | {
"age": 85,
"sex": "female",
"bmi": 20.6,
"smoking_pack_years": 48,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.3,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2024-06-18T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -78
},
"pfs_months": 20.44
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-03-06T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 31.7,
"censored": false
} | [
{
"date": "2024-04-12T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 10.9,
"platelets_k_uL": 157,
"creatinine_mg_dL": 0.89,
"alt_U_L": 72
},
{
"date": "2024-12-15T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 8.3,
"platelets_k_uL": 369,
"creatinine_mg_dL": 1.01,
... |
ANODE_SYNTH_2025_018 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 66,
"sex": "female",
"bmi": 34.7,
"smoking_pack_years": 17,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.4,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-12-01T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -20,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 24.67
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-01-03T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 34.3,
"censored": false
} | [
{
"date": "2020-09-23T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 11,
"platelets_k_uL": 203,
"creatinine_mg_dL": 0.61,
"alt_U_L": 73
},
{
"date": "2021-05-30T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 4.1,
"platelets_k_uL": 204,
"creatinine_mg_dL": 1.15,
... |
ANODE_SYNTH_2025_019 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 76,
"sex": "female",
"bmi": 36.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"bone",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-02-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 28.88
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-08-08T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 48,
"censored": true
} | [
{
"date": "2022-12-11T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 4.7,
"platelets_k_uL": 168,
"creatinine_mg_dL": 0.6,
"alt_U_L": 42
},
{
"date": "2023-08-02T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 5.3,
"platelets_k_uL": 292,
"creatinine_mg_dL": 1.31,
"a... |
ANODE_SYNTH_2025_020 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 24
} | {
"age": 59,
"sex": "female",
"bmi": 29.3,
"smoking_pack_years": 10,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.4,
"metastatic_sites": [
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-01-31T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -11,
"peak_response_20wk_change_percent": -68
},
"pfs_months": 15.7
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-07-04T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 24.3,
"censored": true
} | [
{
"date": "2020-12-13T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 8.9,
"platelets_k_uL": 295,
"creatinine_mg_dL": 0.73,
"alt_U_L": 57
},
{
"date": "2021-07-30T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 5.9,
"platelets_k_uL": 246,
"creatinine_mg_dL": 1.16,
"... |
ANODE_SYNTH_2025_021 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 84,
"sex": "female",
"bmi": 23.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 4,
"metastatic_sites": [
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-11-24T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 28.35
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-04-27T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 43.1,
"censored": false
} | [
{
"date": "2022-11-06T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 7.9,
"platelets_k_uL": 227,
"creatinine_mg_dL": 0.7,
"alt_U_L": 68
},
{
"date": "2023-05-23T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 5.3,
"platelets_k_uL": 149,
"creatinine_mg_dL": 0.81,
"a... |
ANODE_SYNTH_2025_022 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 53,
"sex": "female",
"bmi": 24.4,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-05-26T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -55,
"peak_response_20wk_change_percent": -84
},
"pfs_months": 33.18
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-03-14T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 49.8,
"censored": false
} | [
{
"date": "2025-03-21T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 6.1,
"platelets_k_uL": 420,
"creatinine_mg_dL": 1.22,
"alt_U_L": 54
},
{
"date": "2025-11-22T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.8,
"platelets_k_uL": 380,
"creatinine_mg_dL": 1.42,
... |
ANODE_SYNTH_2025_023 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 3.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 79,
"sex": "female",
"bmi": 29.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-06-21T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -40,
"peak_response_20wk_change_percent": -75
},
"pfs_months": 23.33
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-07-12T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 31.6,
"censored": false
} | [
{
"date": "2024-05-21T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 9.2,
"platelets_k_uL": 249,
"creatinine_mg_dL": 1.27,
"alt_U_L": 70
},
{
"date": "2024-12-18T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 4.4,
"platelets_k_uL": 187,
"creatinine_mg_dL": 1.54,
"... |
ANODE_SYNTH_2025_024 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 63,
"sex": "female",
"bmi": 29.8,
"smoking_pack_years": 78,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-09-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 35.75
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-09-29T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 56.9,
"censored": false
} | [
{
"date": "2020-08-27T00:00:00",
"hemoglobin_g_dL": 14.4,
"wbc_k_uL": 10.1,
"platelets_k_uL": 264,
"creatinine_mg_dL": 0.98,
"alt_U_L": 64
},
{
"date": "2021-03-09T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 6.5,
"platelets_k_uL": 176,
"creatinine_mg_dL": 1.24,
... |
ANODE_SYNTH_2025_025 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 84,
"sex": "female",
"bmi": 27.5,
"smoking_pack_years": 46,
"ecog_performance_status": 0,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 5.4,
"metastatic_sites": [
"brain",
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2024-03-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -38,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 37.19
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-05-21T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 64.4,
"censored": false
} | [
{
"date": "2024-02-06T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 9.7,
"platelets_k_uL": 393,
"creatinine_mg_dL": 1.28,
"alt_U_L": 33
},
{
"date": "2024-08-30T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 4.5,
"platelets_k_uL": 247,
"creatinine_mg_dL": 1.3,
... |
ANODE_SYNTH_2025_026 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 48,
"sex": "female",
"bmi": 32.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.3,
"metastatic_sites": [
"pleura",
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-04-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -32
},
"pfs_months": 31.18
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-01-01T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 50,
"censored": false
} | [
{
"date": "2025-03-13T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 6,
"platelets_k_uL": 177,
"creatinine_mg_dL": 1.25,
"alt_U_L": 63
},
{
"date": "2025-10-17T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 7.2,
"platelets_k_uL": 367,
"creatinine_mg_dL": 0.88,
"... |
ANODE_SYNTH_2025_027 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 14
} | {
"age": 63,
"sex": "female",
"bmi": 31.1,
"smoking_pack_years": 63,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.7,
"metastatic_sites": [
"bone",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-05-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 23.82
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-06-30T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 31,
"censored": false
} | [
{
"date": "2022-03-01T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 8.7,
"platelets_k_uL": 363,
"creatinine_mg_dL": 0.73,
"alt_U_L": 16
},
{
"date": "2022-11-06T00:00:00",
"hemoglobin_g_dL": 10.4,
"wbc_k_uL": 8.7,
"platelets_k_uL": 221,
"creatinine_mg_dL": 1.25,
... |
ANODE_SYNTH_2025_028 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 13.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 88,
"sex": "male",
"bmi": 24.8,
"smoking_pack_years": 14,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 4.9,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-04-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -72
},
"pfs_months": 34.2
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-04-20T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 52.8,
"censored": false
} | [
{
"date": "2022-03-20T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 6.9,
"platelets_k_uL": 290,
"creatinine_mg_dL": 0.86,
"alt_U_L": 14
},
{
"date": "2022-10-17T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 4.1,
"platelets_k_uL": 359,
"creatinine_mg_dL": 1.56,
... |
ANODE_SYNTH_2025_029 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 3.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 10
} | {
"age": 63,
"sex": "female",
"bmi": 24.4,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"bone",
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-04-02T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -50
},
"pfs_months": 26.25
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-08-06T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 38.6,
"censored": false
} | [
{
"date": "2023-03-07T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 9.3,
"platelets_k_uL": 212,
"creatinine_mg_dL": 0.68,
"alt_U_L": 65
},
{
"date": "2023-09-29T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 5,
"platelets_k_uL": 296,
"creatinine_mg_dL": 0.82,
"... |
ANODE_SYNTH_2025_030 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 59,
"sex": "female",
"bmi": 25.9,
"smoking_pack_years": 55,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-12-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 32.49
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-11-03T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 56.9,
"censored": true
} | [
{
"date": "2020-12-05T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 10,
"platelets_k_uL": 299,
"creatinine_mg_dL": 1.19,
"alt_U_L": 55
},
{
"date": "2021-06-29T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 6.6,
"platelets_k_uL": 268,
"creatinine_mg_dL": 1.5,
"... |
ANODE_SYNTH_2025_031 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 65,
"sex": "female",
"bmi": 34.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"brain",
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-05-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 20.83
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-03-17T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 31.6,
"censored": false
} | [
{
"date": "2021-03-10T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 5.2,
"platelets_k_uL": 290,
"creatinine_mg_dL": 1.12,
"alt_U_L": 59
},
{
"date": "2021-11-02T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 6.4,
"platelets_k_uL": 183,
"creatinine_mg_dL": 0.85,
... |
ANODE_SYNTH_2025_032 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 13,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 77,
"sex": "female",
"bmi": 34.1,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-03-29T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -57,
"peak_response_20wk_change_percent": -32
},
"pfs_months": 32.23
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-12-28T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 46.3,
"censored": false
} | [
{
"date": "2023-02-23T00:00:00",
"hemoglobin_g_dL": 15.4,
"wbc_k_uL": 5.7,
"platelets_k_uL": 196,
"creatinine_mg_dL": 1.24,
"alt_U_L": 25
},
{
"date": "2023-09-25T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 4.7,
"platelets_k_uL": 264,
"creatinine_mg_dL": 1.36,
... |
ANODE_SYNTH_2025_033 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 64,
"sex": "male",
"bmi": 18.7,
"smoking_pack_years": 30,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.1,
"metastatic_sites": [
"pleura",
"contralateral lung",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-11-01T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -46
},
"pfs_months": 11.66
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-11-03T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 17.2,
"censored": true
} | [
{
"date": "2021-10-05T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 9.4,
"platelets_k_uL": 441,
"creatinine_mg_dL": 1,
"alt_U_L": 40
},
{
"date": "2022-04-30T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 4.2,
"platelets_k_uL": 220,
"creatinine_mg_dL": 1.32,
"a... |
ANODE_SYNTH_2025_034 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 61,
"sex": "male",
"bmi": 21.6,
"smoking_pack_years": 31,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2024-02-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 43.2
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-11-03T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 62.8,
"censored": false
} | [
{
"date": "2024-01-16T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 9,
"platelets_k_uL": 326,
"creatinine_mg_dL": 0.74,
"alt_U_L": 26
},
{
"date": "2024-08-16T00:00:00",
"hemoglobin_g_dL": 11.4,
"wbc_k_uL": 5.4,
"platelets_k_uL": 236,
"creatinine_mg_dL": 0.72,
"al... |
ANODE_SYNTH_2025_035 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 48,
"sex": "female",
"bmi": 35.6,
"smoking_pack_years": 22,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 4,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-05-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -63
},
"pfs_months": 10.09
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-05-06T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 17.1,
"censored": false
} | [
{
"date": "2024-04-01T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 10.6,
"platelets_k_uL": 364,
"creatinine_mg_dL": 1.16,
"alt_U_L": 76
},
{
"date": "2024-11-23T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 7.7,
"platelets_k_uL": 337,
"creatinine_mg_dL": 1.06,
... |
ANODE_SYNTH_2025_036 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 69,
"sex": "female",
"bmi": 32.4,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.1,
"metastatic_sites": [
"liver",
"bone",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-11-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 17.51
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-06-11T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 29.1,
"censored": false
} | [
{
"date": "2021-10-18T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 9.3,
"platelets_k_uL": 246,
"creatinine_mg_dL": 0.93,
"alt_U_L": 17
},
{
"date": "2022-05-14T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 8,
"platelets_k_uL": 377,
"creatinine_mg_dL": 1.37,
"... |
ANODE_SYNTH_2025_037 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 83,
"sex": "female",
"bmi": 25.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-09-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -77
},
"pfs_months": 20.5
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-06-19T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 32.7,
"censored": false
} | [
{
"date": "2023-09-05T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 6.2,
"platelets_k_uL": 248,
"creatinine_mg_dL": 1.2,
"alt_U_L": 28
},
{
"date": "2024-03-23T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6,
"platelets_k_uL": 150,
"creatinine_mg_dL": 1.47,
"a... |
ANODE_SYNTH_2025_038 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 63,
"sex": "female",
"bmi": 19.9,
"smoking_pack_years": 11,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.6,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-08-02T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -38
},
"pfs_months": 34.89
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-07-17T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 66.4,
"censored": false
} | [
{
"date": "2020-06-21T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 10.9,
"platelets_k_uL": 247,
"creatinine_mg_dL": 1.13,
"alt_U_L": 37
},
{
"date": "2021-01-29T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 8.8,
"platelets_k_uL": 353,
"creatinine_mg_dL": 1.31,
... |
ANODE_SYNTH_2025_039 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 24
} | {
"age": 82,
"sex": "female",
"bmi": 33.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 4.1,
"metastatic_sites": [
"bone",
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-05-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -47
},
"pfs_months": 24.44
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-07-02T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 38.7,
"censored": true
} | [
{
"date": "2020-04-05T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 9.7,
"platelets_k_uL": 229,
"creatinine_mg_dL": 0.61,
"alt_U_L": 53
},
{
"date": "2020-11-26T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 4.5,
"platelets_k_uL": 132,
"creatinine_mg_dL": 1.39,
... |
ANODE_SYNTH_2025_040 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 84,
"sex": "female",
"bmi": 27.4,
"smoking_pack_years": 46,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-07-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -63
},
"pfs_months": 44.91
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-05-11T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 73.7,
"censored": false
} | [
{
"date": "2022-06-10T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 5.7,
"platelets_k_uL": 300,
"creatinine_mg_dL": 0.97,
"alt_U_L": 71
},
{
"date": "2022-12-31T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 4.4,
"platelets_k_uL": 203,
"creatinine_mg_dL": 1.51,
... |
ANODE_SYNTH_2025_041 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 59,
"sex": "female",
"bmi": 29,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-12-16T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 28.78
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-06-26T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 43.4,
"censored": false
} | [
{
"date": "2024-10-16T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 6,
"platelets_k_uL": 202,
"creatinine_mg_dL": 1.03,
"alt_U_L": 14
},
{
"date": "2025-06-14T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 5.2,
"platelets_k_uL": 151,
"creatinine_mg_dL": 1.14,
"... |
ANODE_SYNTH_2025_042 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3
} | {
"age": 88,
"sex": "female",
"bmi": 18.8,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-10-14T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -76
},
"pfs_months": 31.24
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-06-19T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 39.8,
"censored": true
} | [
{
"date": "2024-08-23T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 4.9,
"platelets_k_uL": 387,
"creatinine_mg_dL": 1.15,
"alt_U_L": 66
},
{
"date": "2025-04-12T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 8.9,
"platelets_k_uL": 204,
"creatinine_mg_dL": 1.35,
"... |
ANODE_SYNTH_2025_043 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 14
} | {
"age": 60,
"sex": "male",
"bmi": 20.8,
"smoking_pack_years": 16,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2024-03-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -16,
"peak_response_20wk_change_percent": -85
},
"pfs_months": 36.11
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-04-28T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 61.8,
"censored": true
} | [
{
"date": "2024-02-19T00:00:00",
"hemoglobin_g_dL": 15.4,
"wbc_k_uL": 5,
"platelets_k_uL": 434,
"creatinine_mg_dL": 0.71,
"alt_U_L": 40
},
{
"date": "2024-09-16T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 5.8,
"platelets_k_uL": 150,
"creatinine_mg_dL": 1.07,
"... |
ANODE_SYNTH_2025_044 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 78,
"sex": "female",
"bmi": 24.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.3,
"metastatic_sites": [
"brain",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-01-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 23.92
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-03-19T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 35.6,
"censored": false
} | [
{
"date": "2024-12-02T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 8.3,
"platelets_k_uL": 275,
"creatinine_mg_dL": 0.76,
"alt_U_L": 45
},
{
"date": "2025-07-19T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 5.1,
"platelets_k_uL": 311,
"creatinine_mg_dL": 0.7,
... |
ANODE_SYNTH_2025_045 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 80,
"sex": "female",
"bmi": 24.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.9,
"metastatic_sites": [
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-11-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -38
},
"pfs_months": 20.7
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-09-28T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 29,
"censored": true
} | [
{
"date": "2022-09-21T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 8.2,
"platelets_k_uL": 336,
"creatinine_mg_dL": 1.28,
"alt_U_L": 11
},
{
"date": "2023-05-11T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 8.2,
"platelets_k_uL": 311,
"creatinine_mg_dL": 0.97,
"... |
ANODE_SYNTH_2025_046 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 75,
"sex": "female",
"bmi": 30.3,
"smoking_pack_years": 47,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.7,
"metastatic_sites": [
"pleura",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-05-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -74
},
"pfs_months": 32.16
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-03-07T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 50.6,
"censored": false
} | [
{
"date": "2025-03-27T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 5.3,
"platelets_k_uL": 190,
"creatinine_mg_dL": 0.73,
"alt_U_L": 60
},
{
"date": "2025-10-31T00:00:00",
"hemoglobin_g_dL": 10,
"wbc_k_uL": 7.3,
"platelets_k_uL": 303,
"creatinine_mg_dL": 0.96,
"... |
ANODE_SYNTH_2025_047 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 87,
"sex": "male",
"bmi": 35.5,
"smoking_pack_years": 69,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6,
"metastatic_sites": [
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-07-25T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 12.98
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-10-09T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 16.9,
"censored": false
} | [
{
"date": "2022-06-22T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 9.6,
"platelets_k_uL": 374,
"creatinine_mg_dL": 1.1,
"alt_U_L": 13
},
{
"date": "2023-01-21T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 4.4,
"platelets_k_uL": 359,
"creatinine_mg_dL": 1.19,
... |
ANODE_SYNTH_2025_048 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 28
} | {
"age": 64,
"sex": "female",
"bmi": 33.9,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"liver",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-04-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 29.96
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-11-05T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 42.5,
"censored": true
} | [
{
"date": "2022-02-27T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 7.2,
"platelets_k_uL": 240,
"creatinine_mg_dL": 1.25,
"alt_U_L": 20
},
{
"date": "2022-10-19T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 5.1,
"platelets_k_uL": 316,
"creatinine_mg_dL": 1.06,
... |
ANODE_SYNTH_2025_049 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 62,
"sex": "female",
"bmi": 25,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-03-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -60
},
"pfs_months": 26.58
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-06-17T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 36.8,
"censored": false
} | [
{
"date": "2020-03-02T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 10.4,
"platelets_k_uL": 189,
"creatinine_mg_dL": 0.81,
"alt_U_L": 19
},
{
"date": "2020-09-16T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 8.8,
"platelets_k_uL": 127,
"creatinine_mg_dL": 0.89,
... |
ANODE_SYNTH_2025_050 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 64,
"sex": "female",
"bmi": 24.1,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-11-01T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -40,
"peak_response_20wk_change_percent": -53
},
"pfs_months": 17.91
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-06-27T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 24.6,
"censored": true
} | [
{
"date": "2021-10-01T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 10.4,
"platelets_k_uL": 165,
"creatinine_mg_dL": 1.18,
"alt_U_L": 80
},
{
"date": "2022-04-30T00:00:00",
"hemoglobin_g_dL": 11.4,
"wbc_k_uL": 5.4,
"platelets_k_uL": 182,
"creatinine_mg_dL": 1.55,
... |
ANODE_SYNTH_2025_051 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 71,
"sex": "female",
"bmi": 37.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.7,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-06-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -85
},
"pfs_months": 26.64
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-11-02T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 40.5,
"censored": true
} | [
{
"date": "2022-04-19T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 7.5,
"platelets_k_uL": 329,
"creatinine_mg_dL": 0.7,
"alt_U_L": 10
},
{
"date": "2022-12-19T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 8.1,
"platelets_k_uL": 232,
"creatinine_mg_dL": 1.36,
"a... |
ANODE_SYNTH_2025_052 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 81,
"sex": "female",
"bmi": 29.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-03-01T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -23,
"peak_response_20wk_change_percent": -77
},
"pfs_months": 11.96
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-03-06T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 31.1,
"censored": false
} | [
{
"date": "2021-01-11T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 10.2,
"platelets_k_uL": 181,
"creatinine_mg_dL": 1.18,
"alt_U_L": 19
},
{
"date": "2021-08-28T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 8.3,
"platelets_k_uL": 127,
"creatinine_mg_dL": 1.54,
... |
ANODE_SYNTH_2025_053 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 13.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19
} | {
"age": 73,
"sex": "female",
"bmi": 20,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 5,
"metastatic_sites": [
"bone",
"brain",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-03-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 18.69
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-10-21T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 36.7,
"censored": true
} | [
{
"date": "2022-02-01T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 6.4,
"platelets_k_uL": 416,
"creatinine_mg_dL": 0.91,
"alt_U_L": 24
},
{
"date": "2022-09-23T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 6.6,
"platelets_k_uL": 191,
"creatinine_mg_dL": 0.94,
... |
ANODE_SYNTH_2025_054 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 55,
"sex": "female",
"bmi": 22,
"smoking_pack_years": 53,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.1,
"metastatic_sites": [
"liver",
"brain",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-06-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -45
},
"pfs_months": 40.8
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-11-06T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 67.3,
"censored": true
} | [
{
"date": "2022-04-03T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 7.3,
"platelets_k_uL": 276,
"creatinine_mg_dL": 1.16,
"alt_U_L": 58
},
{
"date": "2022-12-01T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 6.3,
"platelets_k_uL": 287,
"creatinine_mg_dL": 0.93,
"... |
ANODE_SYNTH_2025_055 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "NTRK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 10
} | {
"age": 77,
"sex": "male",
"bmi": 23.9,
"smoking_pack_years": 62,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 7.9,
"metastatic_sites": [
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "larotrectinib 100 mg BID",
"start_date": "2022-05-11T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 15.47
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-09-24T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 34,
"censored": true
} | [
{
"date": "2022-03-04T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 10.3,
"platelets_k_uL": 230,
"creatinine_mg_dL": 1.28,
"alt_U_L": 38
},
{
"date": "2022-11-07T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 7.4,
"platelets_k_uL": 259,
"creatinine_mg_dL": 1.34,
... |
ANODE_SYNTH_2025_056 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 76,
"sex": "female",
"bmi": 22.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.6,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-02-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -44,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 15.54
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-06-09T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 29.8,
"censored": true
} | [
{
"date": "2021-01-26T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.1,
"platelets_k_uL": 239,
"creatinine_mg_dL": 1.09,
"alt_U_L": 47
},
{
"date": "2021-08-11T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 7.9,
"platelets_k_uL": 174,
"creatinine_mg_dL": 1.35,
"... |
ANODE_SYNTH_2025_057 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 70,
"sex": "female",
"bmi": 25.2,
"smoking_pack_years": 62,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.5,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-08-26T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -33,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 37.82
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-11-08T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 56.4,
"censored": false
} | [
{
"date": "2020-08-05T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 10,
"platelets_k_uL": 338,
"creatinine_mg_dL": 1.01,
"alt_U_L": 77
},
{
"date": "2021-02-22T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 8.7,
"platelets_k_uL": 204,
"creatinine_mg_dL": 0.81,
... |
ANODE_SYNTH_2025_058 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0
} | {
"age": 61,
"sex": "male",
"bmi": 19.9,
"smoking_pack_years": 35,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-05-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 16.07
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-10-23T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 31.6,
"censored": true
} | [
{
"date": "2023-04-19T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 9.7,
"platelets_k_uL": 383,
"creatinine_mg_dL": 0.78,
"alt_U_L": 76
},
{
"date": "2023-11-03T00:00:00",
"hemoglobin_g_dL": 10.1,
"wbc_k_uL": 5.4,
"platelets_k_uL": 359,
"creatinine_mg_dL": 0.92,
... |
ANODE_SYNTH_2025_059 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 56,
"sex": "male",
"bmi": 33.7,
"smoking_pack_years": 59,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.1,
"metastatic_sites": [
"contralateral lung",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-06-08T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 34.23
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-04-30T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 51.4,
"censored": false
} | [
{
"date": "2025-04-02T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 10.4,
"platelets_k_uL": 318,
"creatinine_mg_dL": 0.92,
"alt_U_L": 77
},
{
"date": "2025-12-05T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 3.8,
"platelets_k_uL": 359,
"creatinine_mg_dL": 1.54,
... |
ANODE_SYNTH_2025_060 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 52,
"sex": "female",
"bmi": 35.2,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.8,
"metastatic_sites": [
"bone",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-12-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -28,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 28.02
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-06-20T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 39.7,
"censored": false
} | [
{
"date": "2020-12-04T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 4.5,
"platelets_k_uL": 234,
"creatinine_mg_dL": 1.02,
"alt_U_L": 46
},
{
"date": "2021-06-26T00:00:00",
"hemoglobin_g_dL": 11.3,
"wbc_k_uL": 4.1,
"platelets_k_uL": 368,
"creatinine_mg_dL": 0.96,
... |
ANODE_SYNTH_2025_061 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 74,
"sex": "female",
"bmi": 22.6,
"smoking_pack_years": 10,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 8.1,
"metastatic_sites": [
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-12-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -71
},
"pfs_months": 23.89
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-01-05T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 47,
"censored": false
} | [
{
"date": "2021-12-13T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 10.3,
"platelets_k_uL": 363,
"creatinine_mg_dL": 1.13,
"alt_U_L": 26
},
{
"date": "2022-06-29T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 7.9,
"platelets_k_uL": 367,
"creatinine_mg_dL": 0.81,
... |
ANODE_SYNTH_2025_062 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 64,
"sex": "female",
"bmi": 29.5,
"smoking_pack_years": 78,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"bone",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-01-13T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 48.03
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2029-03-03T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 70.4,
"censored": false
} | [
{
"date": "2024-11-24T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 9.8,
"platelets_k_uL": 358,
"creatinine_mg_dL": 0.7,
"alt_U_L": 18
},
{
"date": "2025-07-12T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 8.1,
"platelets_k_uL": 324,
"creatinine_mg_dL": 1.51,
"a... |
ANODE_SYNTH_2025_063 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 65,
"sex": "female",
"bmi": 23.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 8.5,
"metastatic_sites": [
"contralateral lung",
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-01-25T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -56,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 14.59
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2021-06-09T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 29,
"censored": true
} | [
{
"date": "2020-01-01T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 10.1,
"platelets_k_uL": 348,
"creatinine_mg_dL": 0.6,
"alt_U_L": 41
},
{
"date": "2020-07-23T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 7.8,
"platelets_k_uL": 155,
"creatinine_mg_dL": 1.12,
... |
ANODE_SYNTH_2025_064 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 66,
"sex": "female",
"bmi": 29.5,
"smoking_pack_years": 79,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"brain",
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-02-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -16,
"peak_response_20wk_change_percent": -78
},
"pfs_months": 35.98
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-03-11T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 55.3,
"censored": false
} | [
{
"date": "2021-12-18T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 6.9,
"platelets_k_uL": 185,
"creatinine_mg_dL": 0.82,
"alt_U_L": 18
},
{
"date": "2022-08-14T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 4,
"platelets_k_uL": 131,
"creatinine_mg_dL": 0.98,
"al... |
ANODE_SYNTH_2025_065 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 76,
"sex": "female",
"bmi": 36.8,
"smoking_pack_years": 12,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.5,
"metastatic_sites": [
"bone",
"brain",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-07-26T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 26.61
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-11-14T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 40.9,
"censored": true
} | [
{
"date": "2025-06-28T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 5.1,
"platelets_k_uL": 241,
"creatinine_mg_dL": 0.75,
"alt_U_L": 33
},
{
"date": "2026-01-22T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 7.5,
"platelets_k_uL": 137,
"creatinine_mg_dL": 1.36,
... |
ANODE_SYNTH_2025_066 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 67,
"sex": "female",
"bmi": 33.7,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.5,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-01-18T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -64
},
"pfs_months": 27.17
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-06-05T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 39,
"censored": false
} | [
{
"date": "2021-11-23T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 9.2,
"platelets_k_uL": 283,
"creatinine_mg_dL": 1.03,
"alt_U_L": 45
},
{
"date": "2022-07-17T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 7.5,
"platelets_k_uL": 368,
"creatinine_mg_dL": 1.11,
"... |
ANODE_SYNTH_2025_067 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 69,
"sex": "female",
"bmi": 23.1,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.3,
"metastatic_sites": [
"brain",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-01-02T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -34
},
"pfs_months": 28.09
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-06-03T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 41.2,
"censored": false
} | [
{
"date": "2021-11-06T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 5.7,
"platelets_k_uL": 344,
"creatinine_mg_dL": 0.75,
"alt_U_L": 23
},
{
"date": "2022-07-01T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 7.6,
"platelets_k_uL": 161,
"creatinine_mg_dL": 1.34,
"... |
ANODE_SYNTH_2025_068 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 25
} | {
"age": 77,
"sex": "male",
"bmi": 20.2,
"smoking_pack_years": 25,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"contralateral lung",
"pleura",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-11-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 20.3
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-10-06T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 24.2,
"censored": false
} | [
{
"date": "2020-10-24T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 10.8,
"platelets_k_uL": 355,
"creatinine_mg_dL": 0.74,
"alt_U_L": 40
},
{
"date": "2021-05-29T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 5.3,
"platelets_k_uL": 180,
"creatinine_mg_dL": 0.77,
... |
ANODE_SYNTH_2025_069 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 58,
"sex": "male",
"bmi": 29,
"smoking_pack_years": 43,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-04-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 41.33
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-11-14T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 61.7,
"censored": false
} | [
{
"date": "2022-02-06T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 7.3,
"platelets_k_uL": 316,
"creatinine_mg_dL": 1.17,
"alt_U_L": 69
},
{
"date": "2022-10-12T00:00:00",
"hemoglobin_g_dL": 10,
"wbc_k_uL": 6.8,
"platelets_k_uL": 274,
"creatinine_mg_dL": 1.14,
"... |
ANODE_SYNTH_2025_070 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 86,
"sex": "female",
"bmi": 26.1,
"smoking_pack_years": 61,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-03-14T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 2.96
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2020-07-13T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 16.6,
"censored": false
} | [
{
"date": "2020-01-21T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 4.9,
"platelets_k_uL": 385,
"creatinine_mg_dL": 1.18,
"alt_U_L": 76
},
{
"date": "2020-09-10T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 4.4,
"platelets_k_uL": 305,
"creatinine_mg_dL": 1.44,
... |
ANODE_SYNTH_2025_071 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 13.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 70,
"sex": "male",
"bmi": 37.6,
"smoking_pack_years": 64,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-03-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -43,
"peak_response_20wk_change_percent": -77
},
"pfs_months": 10.09
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2021-03-04T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 22.7,
"censored": false
} | [
{
"date": "2020-02-19T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 7,
"platelets_k_uL": 197,
"creatinine_mg_dL": 0.69,
"alt_U_L": 12
},
{
"date": "2020-09-14T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 4.5,
"platelets_k_uL": 206,
"creatinine_mg_dL": 0.85,
"... |
ANODE_SYNTH_2025_072 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 83,
"sex": "female",
"bmi": 22.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-03-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 22.67
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-03-23T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 33.3,
"censored": false
} | [
{
"date": "2021-01-22T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 9.7,
"platelets_k_uL": 448,
"creatinine_mg_dL": 0.88,
"alt_U_L": 31
},
{
"date": "2021-08-30T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 5.1,
"platelets_k_uL": 379,
"creatinine_mg_dL": 1.25,
... |
ANODE_SYNTH_2025_073 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 76,
"sex": "female",
"bmi": 19.4,
"smoking_pack_years": 22,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"liver",
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-02-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 14.52
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-05-21T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 23.9,
"censored": false
} | [
{
"date": "2022-01-24T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 7.4,
"platelets_k_uL": 340,
"creatinine_mg_dL": 1.16,
"alt_U_L": 11
},
{
"date": "2022-08-06T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 7.2,
"platelets_k_uL": 284,
"creatinine_mg_dL": 0.72,
... |
ANODE_SYNTH_2025_074 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 24
} | {
"age": 79,
"sex": "female",
"bmi": 35,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 8,
"metastatic_sites": [
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-05-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -32,
"peak_response_20wk_change_percent": -76
},
"pfs_months": 26.25
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-08-20T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 41.1,
"censored": false
} | [
{
"date": "2021-04-16T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 5.1,
"platelets_k_uL": 392,
"creatinine_mg_dL": 0.87,
"alt_U_L": 30
},
{
"date": "2021-11-21T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 5.4,
"platelets_k_uL": 124,
"creatinine_mg_dL": 1.19,
... |
ANODE_SYNTH_2025_075 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 85,
"sex": "female",
"bmi": 21.8,
"smoking_pack_years": 44,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 5,
"metastatic_sites": [
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-09-13T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 17.91
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-03-27T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 26.8,
"censored": false
} | [
{
"date": "2020-07-11T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 7.9,
"platelets_k_uL": 172,
"creatinine_mg_dL": 0.7,
"alt_U_L": 63
},
{
"date": "2021-03-12T00:00:00",
"hemoglobin_g_dL": 10.7,
"wbc_k_uL": 8.5,
"platelets_k_uL": 232,
"creatinine_mg_dL": 1.37,
... |
ANODE_SYNTH_2025_076 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 86,
"sex": "female",
"bmi": 24.9,
"smoking_pack_years": 28,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-05-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -55
},
"pfs_months": 18
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-12-10T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 28.2,
"censored": false
} | [
{
"date": "2023-03-12T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 7.2,
"platelets_k_uL": 259,
"creatinine_mg_dL": 0.95,
"alt_U_L": 16
},
{
"date": "2023-11-01T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 3.8,
"platelets_k_uL": 131,
"creatinine_mg_dL": 1.6,
... |
ANODE_SYNTH_2025_077 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 78,
"sex": "female",
"bmi": 24.2,
"smoking_pack_years": 16,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.4,
"metastatic_sites": [
"pleura",
"brain",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-12-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 27.6
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-04-29T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 55.9,
"censored": true
} | [
{
"date": "2022-10-11T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 5.2,
"platelets_k_uL": 200,
"creatinine_mg_dL": 1.13,
"alt_U_L": 18
},
{
"date": "2023-06-18T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 7.9,
"platelets_k_uL": 236,
"creatinine_mg_dL": 1.36,
... |
ANODE_SYNTH_2025_078 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 85,
"sex": "male",
"bmi": 37.6,
"smoking_pack_years": 75,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"brain",
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-05-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -61
},
"pfs_months": 13.14
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2021-08-16T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 19.6,
"censored": true
} | [
{
"date": "2020-04-16T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 7.7,
"platelets_k_uL": 390,
"creatinine_mg_dL": 0.92,
"alt_U_L": 78
},
{
"date": "2020-11-21T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 3.9,
"platelets_k_uL": 361,
"creatinine_mg_dL": 1.31,
"... |
ANODE_SYNTH_2025_079 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 68,
"sex": "female",
"bmi": 29.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.1,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-12-27T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -11,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 20.5
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-10-11T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 38.7,
"censored": false
} | [
{
"date": "2023-11-08T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 5.3,
"platelets_k_uL": 312,
"creatinine_mg_dL": 0.74,
"alt_U_L": 34
},
{
"date": "2024-06-24T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 5.7,
"platelets_k_uL": 355,
"creatinine_mg_dL": 1.26,
... |
ANODE_SYNTH_2025_080 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 52,
"sex": "female",
"bmi": 35,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"contralateral lung",
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-12-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 23.52
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-12-17T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"none"
]
}
} | {
"overall_survival_months": 40.4,
"censored": true
} | [
{
"date": "2021-11-07T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 9.4,
"platelets_k_uL": 290,
"creatinine_mg_dL": 0.86,
"alt_U_L": 12
},
{
"date": "2022-06-02T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 8,
"platelets_k_uL": 169,
"creatinine_mg_dL": 1.21,
"al... |
ANODE_SYNTH_2025_081 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 61,
"sex": "female",
"bmi": 36,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.6,
"metastatic_sites": [
"liver",
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-02-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -46
},
"pfs_months": 24.44
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-03-24T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 35.7,
"censored": true
} | [
{
"date": "2021-01-16T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 4.8,
"platelets_k_uL": 346,
"creatinine_mg_dL": 0.8,
"alt_U_L": 47
},
{
"date": "2021-08-21T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 5.4,
"platelets_k_uL": 263,
"creatinine_mg_dL": 1.41,
... |
ANODE_SYNTH_2025_082 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 24
} | {
"age": 56,
"sex": "female",
"bmi": 21.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"liver",
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-09-30T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -38,
"peak_response_20wk_change_percent": -34
},
"pfs_months": 22.11
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-08-26T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 40,
"censored": false
} | [
{
"date": "2025-08-15T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 8.8,
"platelets_k_uL": 433,
"creatinine_mg_dL": 0.79,
"alt_U_L": 47
},
{
"date": "2026-03-29T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 6,
"platelets_k_uL": 308,
"creatinine_mg_dL": 1.47,
"al... |
ANODE_SYNTH_2025_083 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 80,
"sex": "male",
"bmi": 26.1,
"smoking_pack_years": 66,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"brain",
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-03-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -39,
"peak_response_20wk_change_percent": -63
},
"pfs_months": 14.95
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2021-07-10T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 30.2,
"censored": false
} | [
{
"date": "2020-01-03T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 6.5,
"platelets_k_uL": 348,
"creatinine_mg_dL": 1.28,
"alt_U_L": 39
},
{
"date": "2020-09-06T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 6.2,
"platelets_k_uL": 144,
"creatinine_mg_dL": 0.88,
... |
ANODE_SYNTH_2025_084 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 66,
"sex": "female",
"bmi": 29.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-04-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -56,
"peak_response_20wk_change_percent": -32
},
"pfs_months": 18.5
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-11-18T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 25.6,
"censored": true
} | [
{
"date": "2023-03-23T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 8.6,
"platelets_k_uL": 178,
"creatinine_mg_dL": 0.69,
"alt_U_L": 10
},
{
"date": "2023-10-09T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 8,
"platelets_k_uL": 244,
"creatinine_mg_dL": 1.35,
"... |
ANODE_SYNTH_2025_085 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 62,
"sex": "female",
"bmi": 34.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-09-16T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -19,
"peak_response_20wk_change_percent": -72
},
"pfs_months": 20.37
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-07-05T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 37.3,
"censored": true
} | [
{
"date": "2022-08-09T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 10.6,
"platelets_k_uL": 414,
"creatinine_mg_dL": 1.07,
"alt_U_L": 61
},
{
"date": "2023-03-15T00:00:00",
"hemoglobin_g_dL": 10.4,
"wbc_k_uL": 8.4,
"platelets_k_uL": 283,
"creatinine_mg_dL": 1.45,
... |
ANODE_SYNTH_2025_086 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 11
} | {
"age": 49,
"sex": "male",
"bmi": 25.8,
"smoking_pack_years": 19,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.4,
"metastatic_sites": [
"liver",
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-10-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -27,
"peak_response_20wk_change_percent": -77
},
"pfs_months": 36.67
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-12-17T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 62,
"censored": true
} | [
{
"date": "2025-10-03T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 7,
"platelets_k_uL": 331,
"creatinine_mg_dL": 1.2,
"alt_U_L": 25
},
{
"date": "2026-04-16T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 6.8,
"platelets_k_uL": 206,
"creatinine_mg_dL": 0.71,
"alt... |
ANODE_SYNTH_2025_087 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 28
} | {
"age": 71,
"sex": "female",
"bmi": 32.7,
"smoking_pack_years": 40,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-08-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 27.2
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-12-04T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 39.9,
"censored": false
} | [
{
"date": "2021-07-11T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 10.8,
"platelets_k_uL": 226,
"creatinine_mg_dL": 0.75,
"alt_U_L": 39
},
{
"date": "2022-02-16T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 4.7,
"platelets_k_uL": 344,
"creatinine_mg_dL": 0.98,
... |
ANODE_SYNTH_2025_088 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 50,
"sex": "male",
"bmi": 21.3,
"smoking_pack_years": 77,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-02-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -57,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 27.04
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-05-18T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 36.5,
"censored": false
} | [
{
"date": "2025-01-19T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 6,
"platelets_k_uL": 363,
"creatinine_mg_dL": 1.03,
"alt_U_L": 55
},
{
"date": "2025-08-05T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 5,
"platelets_k_uL": 294,
"creatinine_mg_dL": 0.89,
"al... |
ANODE_SYNTH_2025_089 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 14
} | {
"age": 88,
"sex": "female",
"bmi": 26.1,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-11-04T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 26.81
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-03-07T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 41.9,
"censored": false
} | [
{
"date": "2025-09-22T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 9.6,
"platelets_k_uL": 338,
"creatinine_mg_dL": 0.66,
"alt_U_L": 64
},
{
"date": "2026-05-03T00:00:00",
"hemoglobin_g_dL": 11.4,
"wbc_k_uL": 7,
"platelets_k_uL": 273,
"creatinine_mg_dL": 0.98,
"... |
ANODE_SYNTH_2025_090 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 86,
"sex": "female",
"bmi": 36.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.6,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-01-02T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 22.7
},
"second_line_therapy": {
"trigger_reason": "radiologic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-01-04T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 27.9,
"censored": false
} | [
{
"date": "2024-12-07T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 9.3,
"platelets_k_uL": 353,
"creatinine_mg_dL": 0.96,
"alt_U_L": 23
},
{
"date": "2025-07-01T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 7,
"platelets_k_uL": 280,
"creatinine_mg_dL": 1.1,
"a... |
ANODE_SYNTH_2025_091 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 11
} | {
"age": 83,
"sex": "female",
"bmi": 37.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 8.1,
"metastatic_sites": [
"contralateral lung",
"pleura",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-07-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -22,
"peak_response_20wk_change_percent": -44
},
"pfs_months": 22.93
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-07-26T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 36.9,
"censored": false
} | [
{
"date": "2024-06-07T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 7.2,
"platelets_k_uL": 203,
"creatinine_mg_dL": 1.27,
"alt_U_L": 80
},
{
"date": "2024-12-30T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 4.1,
"platelets_k_uL": 228,
"creatinine_mg_dL": 1.09,
... |
ANODE_SYNTH_2025_092 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 64,
"sex": "female",
"bmi": 34,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.4,
"metastatic_sites": [
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-10-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -22,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 20.37
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-07-05T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 33.1,
"censored": false
} | [
{
"date": "2023-09-16T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 5.6,
"platelets_k_uL": 265,
"creatinine_mg_dL": 0.66,
"alt_U_L": 49
},
{
"date": "2024-04-04T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 6,
"platelets_k_uL": 251,
"creatinine_mg_dL": 1.34,
"al... |
ANODE_SYNTH_2025_093 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 87,
"sex": "female",
"bmi": 20,
"smoking_pack_years": 77,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"bone",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-10-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -85
},
"pfs_months": 23.39
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-11-18T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 35,
"censored": false
} | [
{
"date": "2024-09-13T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 10.1,
"platelets_k_uL": 429,
"creatinine_mg_dL": 1.29,
"alt_U_L": 32
},
{
"date": "2025-04-08T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 5.6,
"platelets_k_uL": 287,
"creatinine_mg_dL": 1.36,
... |
ANODE_SYNTH_2025_094 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 53,
"sex": "male",
"bmi": 31,
"smoking_pack_years": 71,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.6,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-09-17T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -13,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 14.98
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-12-24T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 30.5,
"censored": true
} | [
{
"date": "2021-07-20T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 5.7,
"platelets_k_uL": 426,
"creatinine_mg_dL": 1.05,
"alt_U_L": 74
},
{
"date": "2022-03-16T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 7.7,
"platelets_k_uL": 262,
"creatinine_mg_dL": 0.9,
... |
ANODE_SYNTH_2025_095 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0
} | {
"age": 81,
"sex": "male",
"bmi": 21.2,
"smoking_pack_years": 37,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.6,
"metastatic_sites": [
"brain",
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-07-29T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 34.79
},
"second_line_therapy": {
"trigger_reason": "new brain metastases",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-07-09T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 74.4,
"censored": false
} | [
{
"date": "2023-05-23T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 10.9,
"platelets_k_uL": 186,
"creatinine_mg_dL": 1.27,
"alt_U_L": 17
},
{
"date": "2024-01-25T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 8,
"platelets_k_uL": 139,
"creatinine_mg_dL": 1.35,
... |
ANODE_SYNTH_2025_096 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 53,
"sex": "female",
"bmi": 19.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"brain",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-05-26T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 23.62
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-06-23T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 45.2,
"censored": false
} | [
{
"date": "2025-04-18T00:00:00",
"hemoglobin_g_dL": 15,
"wbc_k_uL": 4.8,
"platelets_k_uL": 321,
"creatinine_mg_dL": 1.02,
"alt_U_L": 26
},
{
"date": "2025-11-22T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 6.6,
"platelets_k_uL": 327,
"creatinine_mg_dL": 1.16,
"... |
ANODE_SYNTH_2025_097 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 53,
"sex": "male",
"bmi": 26.6,
"smoking_pack_years": 35,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-08-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -55,
"peak_response_20wk_change_percent": -31
},
"pfs_months": 43.47
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-04-23T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 anemia"
]
}
} | {
"overall_survival_months": 74.9,
"censored": false
} | [
{
"date": "2023-07-07T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 6.5,
"platelets_k_uL": 171,
"creatinine_mg_dL": 0.98,
"alt_U_L": 50
},
{
"date": "2024-02-10T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 5.9,
"platelets_k_uL": 140,
"creatinine_mg_dL": 1.07,
... |
ANODE_SYNTH_2025_098 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 74,
"sex": "female",
"bmi": 24.4,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-06-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -50
},
"pfs_months": 30.13
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-01-14T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 2 anemia",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 39.4,
"censored": false
} | [
{
"date": "2021-05-03T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.3,
"platelets_k_uL": 390,
"creatinine_mg_dL": 1.28,
"alt_U_L": 58
},
{
"date": "2021-12-14T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 4.5,
"platelets_k_uL": 257,
"creatinine_mg_dL": 1.04,
... |
ANODE_SYNTH_2025_099 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 64,
"sex": "female",
"bmi": 29,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"brain",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-07-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -71
},
"pfs_months": 18.69
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-02-23T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"Grade 1 nausea",
"none"
]
}
} | {
"overall_survival_months": 28.6,
"censored": true
} | [
{
"date": "2020-05-11T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 5.8,
"platelets_k_uL": 308,
"creatinine_mg_dL": 1.08,
"alt_U_L": 23
},
{
"date": "2021-01-01T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 7.7,
"platelets_k_uL": 195,
"creatinine_mg_dL": 0.81,
... |
ANODE_SYNTH_2025_100 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 80,
"sex": "male",
"bmi": 35.8,
"smoking_pack_years": 63,
"ecog_performance_status": 2,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-07-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -44
},
"pfs_months": 7.89
},
"second_line_therapy": {
"trigger_reason": "symptomatic progression",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-05-07T00:00:00",
"best_response": "Stable disease",
"toxicity_grade": [
"none",
"Grade 1 nausea"
]
}
} | {
"overall_survival_months": 11.8,
"censored": false
} | [
{
"date": "2025-05-27T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 7.4,
"platelets_k_uL": 363,
"creatinine_mg_dL": 1.01,
"alt_U_L": 70
},
{
"date": "2026-01-26T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 3.9,
"platelets_k_uL": 231,
"creatinine_mg_dL": 0.75,
... |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 463